Regeneron Pharma: FDA Okays EYLEA Injection SBLA In Wet AMD

Regeneron Pharmaceuticals, Inc. (REGN) said that the U.S. Food and Drug Administration or FDA has approved a supplemental Biologics License Application or sBLA for Eylea (aflibercept) Injection in patients with wet age-related macular degeneration or wet AMD.

from RTT - Biotech https://ift.tt/2BkyVUa
via IFTTT